Lundbeck appoints strategy executives
This article was originally published in Scrip
Trailing an expected 18 month new medicines launch programme, Lundbeck has appointed Andreas Eggert as senior vice president for global product strategy and Klaus Abel as vice president with responsibility for commercialisation of medicines from the Danish company's partnership with Otsuka Pharmaceuticals. Since joining Lundbeck in 2010, Mr Eggert has driven marketing strategy development and execution of new medicines. He reports to president and CEO Ulf Wiinberg. Mr Abel, who will report to Mr Eggert, will have special focus on collaborative development and commercialisation of two medicines: once monthly aripiprazole for treatment of schizophrenia, and brexpiprazole (OPC-34712) for treatment of schizophrenia and major depression.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.